# US 2024/0197921 A1 · Signal peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197921 A1
- Document ID: US20240197921A1
- Status: Published application
- Kind: A1
- Application number: 18/555,385
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-13
- Assignees: Imperial College Innovations Limited
- Applicants: Imperial College Innovations Limited
- Inventors: Jack HICKMOTT; Eric ALTON; Uta GRIESENBACH; Possawee PRASERTSUK
- Web page: https://patentgrep.com/patent/US20240197921A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 14/005: from viruses
- C07K 14/47: from mammals
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 14/8125: {Alpha-1-antitrypsin}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/86: Viral vectors
- C12Y 301/06013: Iduronate-2-sulfatase (3.1.6.13)
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C07K 2319/02: containing a signal sequence
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2760/18822: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2810/85: mammalian
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to nucleic acid cassettes for gene therapy, particularly to nucleic acid cassettes encoding therapeutic proteins in combination with exogenous signal peptides. The invention further relates to viral and non-viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by airway cells.

## Claims

### Claim 1

A nucleic acid cassette comprising:
(a) a nucleic acid sequence encoding an exogenous signal peptide; and
(b) a nucleic acid sequence encoding a therapeutic protein;
wherein the exogenous signal peptide (i) increases secretion of the therapeutic protein from airway cells and/or (ii) increases insertion of the therapeutic protein into the cell membrane of airway cells.

### Claim 2 (depends on 1)

The nucleic acid cassette of claim 1, wherein the exogenous signal peptide is capable of:
(a) increasing secretion of the therapeutic protein as compared to secretion of the therapeutic protein without the exogenous signal peptide; and/or
(b) increasing secretion of the therapeutic protein as compared to secretion of the therapeutic protein with its endogenous signal peptide.

### Claim 3 (depends on 1)

The nucleic acid cassette of claim 1, wherein the exogenous signal peptide is capable of:
(a) increasing insertion of the therapeutic protein into the cell membrane of airway cells as compared to membrane insertion of the therapeutic protein without the exogenous signal peptide; and/or
(b) increasing insertion of the therapeutic protein into the cell membrane of airway cells as compared to membrane insertion of the therapeutic protein with its endogenous signal peptide.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid cassette of any one of claims 1 to 3, wherein the exogenous signal peptide is a signal peptide that drives high secretion from and/or membrane insertion by airway cells, wherein optionally the exogenous signal peptide is selected from:
(a) a cartilage acidic protein 1 (CRTAC1) signal peptide;
(b) a uteroglobin (SCGB1A1) signal peptide;
(c) an alpha-2-macroglobulin (A2M) signal peptide;
(d) a synthetic signal peptide;
(e) a pulmonary surfactant associated protein A (SFTPA2) signal peptide;
(f) a fibronectin (CLEC3B) signal peptide;
(g) an alpha-1-antitrypsin (AAT) signal peptide;
(h) a granulocyte-macrophage Colony-stimulating factor (GM-CSF) signal peptide;
(i) an iduronate 2-sulfatase (IDS) signal peptide; and
(j) a hybrid signal peptide, optionally a hybrid of an ATT signal peptide and a synthetic signal peptide.

### Claim 5

The nucleic acid cassette of any one of the preceding claims, wherein the exogenous signal peptide comprises or consists of:
(a) an amino acid sequence having at least 90% identity to an amino acid selected from the group consisting of: SEQ ID NOs: 1-12; or
(b) an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-12.

### Claim 6

The nucleic acid cassette of any one of the preceding claims, wherein the nucleic acid sequence encoding the exogenous signal peptide is 5′ of the nucleic acid sequence encoding the therapeutic protein.

### Claim 7

The nucleic acid cassette of any one of the preceding claims, which further comprises a promoter configured to express the nucleic acid sequence encoding the exogenous signal peptide and the therapeutic protein.

### Claim 8 (depends on 7)

The nucleic acid cassette of claim 7, wherein the promote is selected from the group consisting of a hybrid human cytomegalovirus (CMV) enhancer/elongation factor 1 a (EF1 a) promoter (hCEF), a CMV promoter and an EF1 a promoter, preferably a hCEF promoter.

### Claim 9

The nucleic acid cassette of any one of the preceding claims further comprising:
(a) a translation initiation sequence; and/or
(b) an internal ribosome entry sequence (IRES).

### Claim 10

The nucleic acid cassette of any one of the preceding claims, wherein the therapeutic protein is:
(a) a secreted therapeutic protein selected from: AAT, Factor VIII, Surfactant Protein B (SP-B), Factor VII, Factor IX, Factor X, Factor XI, van Willebrand Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Surfactant Protein C (SP-C), decorin, an anti-inflammatory protein (e.g. IL-10 or TGFβ) or monoclonal antibody, an anti-inflammatory decoy, or a monoclonal antibody against an infectious agent; or
(b) CFTR, TRIM72, CSF2RA, CSF2RB or ATP-binding cassette sub-family A member 3 (ABCA3).

### Claim 11

The nucleic acid cassette of any one of the preceding claims, wherein the airway cells are:
(a) lung cells; and/or
(b) selected from epithelial cells, basal cells, submucosal gland duct cells, club cells, neuroendocrine cells, bronchoalveolar stem cells, submucosal acinar cells, ionocytes, type I pneumocytes and/or type II pneumocytes.

### Claim 12

A gene therapy vector, comprising a nucleic acid cassette as defined in any one of the preceding claims.

### Claim 13 (depends on 12)

The gene therapy vector of claim 12, which is a non-viral vector, wherein optionally:
(a) the non-viral vector is a plasmid; and/or
(b) the non-viral vector is comprised in a cationic liposome, which preferably comprises GL67A.

### Claim 14 (depends on 12)

The gene therapy vector of claim 12, which is a viral vector, optionally selected from:
(a) a lentiviral vector;
(b) an AAV vector;
(c) an adenoviral vector; and
(d) a sendai virus vector.

### Claim 15 (depends on 14)

The gene therapy vector of claim 14, which is a lentiviral vector that is pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus.

### Claim 16 (depends on 15)

The gene therapy vector of claim 15, wherein the respiratory paramyxovirus is a Sendai virus.

### Claim 17 (depends on 14, 15, 16)

The gene therapy vector of any one of claims 14-16, wherein the lentiviral vector is selected from the group consisting of a Human immunodeficiency virus (HIV) vector, a Simian immunodeficiency virus (SIV) vector, a Feline immunodeficiency virus (FIV) vector, an Equine infectious anaemia virus (EIAV) vector, and a Visna/maedi virus vector.

### Claim 18 (depends on 17)

The gene therapy vector of claim 17, wherein the lentiviral vector is a SIV vector.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of expressing a secreted therapeutic protein in a target cell, comprising delivering a nucleic acid cassette as defined in any one of claims 1-11 or a gene therapy vector as defined in any one of claims 12-18 into the target cells.

### Claim 20 (depends on 19)

The method of claim 19, wherein said delivering comprises integrating said nucleic acid cassette or gene therapy vector into said target cell's genome.

### Claim 21 (depends on 12, 13, 14, 15, 16, 17, 18)

A gene therapy vector as defined in any one of claims 12-18 for use in a method of treating a disease.

### Claim 22 (depends on 21)

The gene therapy vector for use of claim 21, wherein the disease is a genetic disease.

### Claim 23 (depends on 21, 22)

The gene therapy vector for use of claim 21 or 22, wherein the disease is:
(a) a respiratory disease, particularly a genetic respiratory disease; or
(b) a cardiovascular disease or blood disorder, particularly a genetic cardiovascular disease or blood disorder.

### Claim 24 (depends on 21, 22, 23)

The gene therapy vector for use of any one of claims 21-23, wherein the disease is selected from cystic fibrosis (CF); Primary Ciliary Dyskinesia (PCD); Surfactant Protein B (SP-B) Deficiency; Alpha 1-antitrypsin Deficiency (A1AD); Pulmonary Alveolar Proteinosis (PAP); Chronic obstructive pulmonary disease (COPD); Pulmonary surfactant metabolism dysfunction 2 (SMDP2); Pulmonary surfactant metabolism dysfunction 3 (SMDP3); Acute respiratory distress syndrome (ARDS); COVID-19; a pulmonary fibrotic disease; a pulmonary allergic condition; a pulmonary bacterial infection; lung cancer; a dysplastic change in the lungs; and haemophilia.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A cell comprising a nucleic acid cassette as defined in any one of claims 1-11 or a gene therapy vector as defined in any one of claims 12-18.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A composition comprising a nucleic acid cassette as defined in any one of claims 1-11 or a gene therapy vector as defined in any one of claims 12-18 and a pharmaceutically acceptable carrier, diluent or excipient.
